Are dopamine receptors present on human lymphocytes?

The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders

Besides its action on the nervous system, dopamine (DA) plays a role on neural-immune interactions. Here we review the current evidence on the dopaminergic system in human peripheral blood lymphocytes (PBL). PBL synthesize DA through the tyrosine-hydroxylase/DOPA-decarboxylase pathway, and express DA receptors and DA transporter (DAT) on their plasma membrane. Stimulation of DA receptors on PBL membrane contributes to modulate the development and initiation of immune responses under physiological conditions and in immune system pathologies such as autoimmunity or immunodeficiency.

The characterization of DA system in PBL gave rise to a further line of research investigating the feasibility of PBL as a cellular model for studying DA derangement in neuropsychiatric disorders. Several reports showed changes of the expression of DAT and/or DA receptors in PBL from patients suffering from several neuropsychiatric disorders, in particular parkinsonian syndromes, schizophrenia and drug- or alcohol-abuse. Despite some methodological and theoretical limitations, these findings suggest that PBL may prove a cellular tool with which to identify the derangement of DA transmission in neuropsychiatric diseases, as well as to monitor the effects of pharmacological treatments.

Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays

Analysis of dopamine receptors (DR) in lymphocytes of the human peripheral blood mononuclear cell (PBMC) fraction is an attractive tool for evaluation of functional properties of dopaminergic function underlying variation in complex psychological/psychopathological traits. Receptor binding assays (RBAs) with selective radioligands, which are widely used in CNS studies, have not produced consistent results when applied to isolated PBMC. We tested the assay conditions that could be essential for detection of DR in human PBMC and their membrane preparations. Using [(3)H]SCH23390, a dopamine D1-like receptor antagonist, we demonstrated the presence of two binding sites in PBMC-derived membrane fraction. One of them is characterized by the K(d) value consistent with that reported for D5 dopamine receptors in human lymphocytes, whereas the other K(d) value possibly corresponds to serotonin receptor(s). Although D5 receptor binding sites in PBMC membranes could be characterized by binding assays, the low protein expression and the large volume of blood needed for membrane preparation render the binding method impracticable for individual phenotyping. In contrast, real-time RT-PCR may be used for this purpose, contingent on the relationship between DR expression in the brain and in lymphocytes. The expression of the DRD2-DRD5 genes, as detected by this method, varied widely among samples, whereas the DRD1 expression was not detected. The expression levels were comparable with those in the brain for DRD3 and DRD4, and were significantly lower for DRD2 and DRD5.

Postnatal development of dopamine receptor expression in rat peripheral blood lymphocytes

Postnatal development in the expression of dopamine D1-like and D2-like receptors was investigated in peripheral blood lymphocytes of male Wistar rats aged 1, 3, 4, 8, 12 and 16 weeks of age by radioligand binding assay techniques. Sample of frontal cortex, striatum and hippocampus were also investigated as reference tissues. The dopamine D1-like receptor antagonist [3H]SCH 23390 and the dopamine D2-like receptor agonist [3H]7-OH-DPAT were used as radioligands. The affinity (K(d)) of [3H]SCH 23390 or of [3H]7-OH-DPAT binding was unchanged in lymphocytes of rats of different age groups. The density (B(max)) of [3H]SCH 23390 binding sites increased from the 1st to the 3rd week of age, remained constant from the 3rd to the 8th week of age, and then increased slightly at 12 and 16 weeks of age. The B(max) value of [3H]7-OH-DPAT binding to lymphocytes increased from the 1st to the 3rd week of age, remained constant from the 3rd to the 4th week, increased again until the 12th week and then plateaued. Dopamine D1-like and D2-like receptor maturation in frontal cortex, hippocampus and striatum revealed an increased receptor density until the 4th week of age and a relative stabilization of receptor density values between the 4th to the 12th week depending on the area considered. Comparatively postnatal maturation of lymphocyte dopamine D1-like receptors displayed a pattern different from that of brain areas investigated, whereas maturation of D2-like receptors displayed a pattern similar to that of striatum. The quantitative and/or qualitative dissimilarities between development of lymphocyte and brain dopamine receptors suggest that from a developmental point of view lymphocyte dopamine receptors probably cannot be considered as a marker of homologous brain receptors.

Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study

1. Peripheral blood lymphocytes express dopamine D1-like and D2-like receptors which were investigated using radioligand binding assay and molecular biology techniques. Analysis of dopamine D2-like receptors expressed by human peripheral blood lymphocytes with radioligand binding assay may offer a rapid technique for assessing receptor changes in disorders characterized by involvement of the dopaminergic system. However, the suitability of radioligand binding assay techniques to measure dopamine D2-like receptors is questioned. 2. In view of the discrepancy between data of dopamine D2-like receptor determination with molecular biology and radioligand binding assay techniques, we have assayed dopamine D2-like receptors expressed by human peripheral blood lymphocytes using as radioligands the dopamine receptor agonist 7-[3H]-hydroxy-N,N-di-n-propyl-2-aminotetraline ([3H]-7-OH-DPAT) and two antagonists ([3H]-spiperone and [3H]-nemonapride). 3. Analysis of saturation curves revealed a concentration-dependent binding of all compounds to human peripheral blood lymphocytes. Dissociation constant (Kd) values averaged between 0.15 and 0.40 nM for different radioligands. The maximum density of binding sites (Bmax) was low, ranging from 4.15 +/- 0.05 fmol/10(6) cells with [3H]-spiperone and 8.66 +/- 0.04 fmol/10(6) cells with [3H]-7-OH-DPAT. 4. Displacement curves of [3H]-7-OH-DPAT, [3H]-spiperone and [3H]-nemonapride binding to human peripheral blood lymphocytes revealed, using radioligand concentrations giving the highest specific:non-specific binding ratio, a pharmacological profile consistent with the labelling of dopamine D2-like receptors. The use of higher radioligand concentrations resulted in a poorly displaceable and characterizable binding. 5. Detection of dopamine D2, D3 and D4 receptor immunoreactivity in cytospin centrifuged peripheral blood lymphocytes revealed dopamine D3 and D4 but not D2 receptor immunostaining. 6. The above findings indicate in agreement with molecular biology studies, that dopamine D2-like receptors expressed by human peripheral blood lymphocytes belong to the D3 and D4 receptor subtypes. These receptors are detectable using either dopamine D2-like receptor agonists and antagonists as radioligands if controlled experimental conditions are followed. The standardisation of immunocytochemical techniques for detecting human peripheral blood lymphocyte dopamine receptors may contribute to clarify their role in lymphocyte function or as a peripheral marker of the status of the dopaminergic system.

Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study

The expression of dopamine D4 receptor was investigated in human peripheral blood lymphocytes with a radioligand binding assay technique, using [3H]clozapine as radioligand. [3H]Clozapine was specifically bound to human peripheral blood lymphocytes. The binding was time-, temperature-, and concentration-dependent and of high affinity, with a dissociation constant (K(d)) value of 0.34 +/- 0.02 nM and a maximum density of binding sites (B(max)) value of 27 +/- 1.4 fmol/10(6) cells. The pharmacological profile of [3H]clozapine binding to human peripheral blood lymphocytes was similar to that found in Chinese hamster ovary (CHO) cells transfected with the D4 clone (D4.2 variant). The above results are consistent with molecular biology studies demonstrating the expression of a dopamine D4 receptor in immune cells and in human peripheral blood lymphocytes. The availability of a rapid and sensitive radioligand binding assay technique for the dopamine D4 receptor in human peripheral blood lymphocytes may contribute to better define the role of this dopamine receptor subtype in neurological and psychiatric disorders.

Inhibition of gamma interferon synthesis by catecholamines

In vitro incubation of Listeria monocytogenes immune spleen cells in the presence of the catecholamines epinephrine or norepinephrine inhibited the gamma interferon (IFN-gamma) synthesis induced by the mitogen PHA, in a manner that appeared to be concentration dependent. Moreover, the inhibitory effect of both catecholamines epinephrine and norepinephrine on the synthesis of IFN-gamma was prevented by incubating immune spleen cells in the presence of propranolol, a beta adrenergic antagonist agent.

Catecholamines inhibit alpha/beta interferon production induced by lipopolysaccharide

In vitro incubation of Listeria monocytogenes immune spleen cells in the presence of the catecholamines epinephrine or norepinephrine inhibited the alpha/beta-interferon (IFN alpha/beta) synthesis induced by the mitogen lipopolysaccharide, in a manner that appeared to be concentration-dependent. Moreover, the inhibitory effect of both catecholamines epinephrine and norepinephrine on the synthesis of IFN alpha/beta was prevented by incubating immune spleen cells in the presence of propranolol, a beta-adrenergic antagonist agent.

3H-spiperone binding to peripheral mononuclear cells in psychiatric in-patients

1. There is an ongoing controversy, if increased binding of 3H-spiperone to lymphocytes might discriminate between schizophrenia and other psychiatric diseases or even be a genetic vulnerability marker for schizophrenia, or predict the response to neuroleptic treatment. 2. Some critical methodological details which might contribute to this controversy are described. 3. 3H-spiperone binding was evaluated in 31 patients with schizophrenia, 7 patients with schizoaffective disorder, bipolar type, 6 patients with a manic episode and 6 patients with a depressive episode of bipolar major affective disorder (DSM-III-R criteria), and in 19 healthy subjects. 4. There were no significant differences in characteristic binding parameters (KD, Bmax) between all groups of psychiatric in-patients and in comparison to healthy subjects. Moreover, there was no relation of binding parameters to any of the subtypes of schizopherenia or to the course of illness according to DSM-III-R-criteria. 5. Neuroleptic treatment or clinical response to treatment had no consistent effect on binding parameters intra-individually. 6. In summary, 3H-spiperone binding to lymphocytes failed to differentiate between the diagnostic subgroups (DSM-III-R) and between treatment responders and non-responders in our sample of patients.

Dopamine D5 receptor expression is unchanged in peripheral blood lymphocytes in essential hypertension

The present study was designed to investigate possible changes in the expression of lymphocyte dopamine receptor in essential hypertension. The expression of dopamine D5 receptor was evaluated by radioligand binding techniques using [3H]-SCH 23390 as ligand. Plasma catecholamines, aldosterone levels and plasma renin activity were also measured. Eleven borderline hypertensive patients, 15 patient with the mild essential hypertension, 7 patients with moderate essential hypertension and 5 patients with severe essential hypertension were examined. Plasma catecholamine levels were assayed by high pressure liquid chromatography with electrochemical detection. Dopamine D5 receptor was measured by radioligand binding techniques. Plasma aldosterone levels and renin activity were determined by radio immunoassay. [3H]-SCH 23390 was specifically bound to human peripheral blood lymphocytes. The binding was time-, temperature- and concentration-dependent with a dissociation constant (Kd) value of 0.59 nM and a maximum density of binding sites (Bmax) of 223 pmol/10(6) cells. Dopamine competed with [3H]-SCH 23390 binding in the submicromolar range suggesting the labelling of a dopamine D5 receptor. No changes in the density of [3H]-SCH 23390 binding sites were observed in human peripheral blood lymphocytes between essential hypertensive patients and normotensive subjects. Also catecholamines, plasma renin activity and aldosterone levels were unchanged. In spite of the availability of a sensitive technique for measuring dopamine receptors in human peripheral lymphocytes, no change in their expression was noticeable in essential hypertension. This suggests that dopamine receptor analysis in essential hypertension is not a useful marker for investigating hypertension-dependent changes of the peripheral dopaminergic system.

Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT

The presence and the pharmacological profile of dopamine D3 receptor have been investigated in human peripheral blood lymphocytes using radioligand binding techniques and the selective dopamine D3 receptor agonist [3H]7-hydroxy-N,N-di-n-pro-pyl-2-aminotetralin ([3H]7-OH-DPAT) as a ligand. [3H]7-OH-DPAT binding to human peripheral blood lymphocytes was time-, temperature-, and concentration-dependent and of high affinity with a dissociation constant value (Kd) of 0.27 +/- 0.05 nM and a maximum binding density (Bmax) of 14.7 +/- 0.06 fmol/2 x 10(6) cells. Binding was also reversible. The rank order of potency of displacers of [3H]7-OH-DPAT binding to human peripheral blood lymphocytes resembled that found for dopamine D3 receptor in rat brain homogenates or in rat or human cell lines. Our findings, which are consistent with those of other authors performed with molecular biology techniques, suggest that human peripheral blood lymphocytes express dopamine D3 receptor. In the brain, dopamine D3 receptor probably mediates the anti-psychotic effect of neuroleptics. The availability of a rapid and reproducible technique for its assay may contribute to evaluate its status in brain disorders characterized by impaired dopaminergic neurotransmission.

Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study

In the present study we have investigated, using radioligand binding techniques and the dopamine receptor antagonist [3H]SCH 23390 as a ligand, the existence of specific dopamine D1-like receptors in human peripheral blood lymphocytes. [3H]SCH 23390 binding to human peripheral blood lymphocytes was time-, temperature-, concentration-dependent and of high affinity with a dissociation constant value (Kd) of 0.58 +/- 0.05 nM and a maximum binding density (Bmax) of 11.02 +/- 0.3 fmol/5 x 10(6) cells. The binding was also reversible. Pharmacological analysis displacement curves of [3H]SCH 23390 binding with dopamine competing with the radioligand in the submicromolar range suggests that peripheral blood lymphocytes express dopamine D5 receptors rather than dopamine D1 receptors. These results, which are consistent with studies performed with molecular biology techniques, suggest that dopamine may modulate peripheral blood lymphocyte activity. Radioligand binding techniques, applied to lymphocyte receptor studies for their feasibility and flexibility may be used to investigate the possible relationship between the immune and dopaminergic systems. Moreover, they could be employed as a tool in Parkinson's disease, migraine, schizophrenia and hypertension research.

Pharmacological characterization and autoradiographic localization of dopamine D1-like receptors in the thymus

The present study was designed to identify the pharmacological profile and the anatomical localisation of dopamine D1-like receptor sites in the rat thymus using [3H]SCH 23390 as a ligand. [3H]SCH 23390 was specifically bound to sections of the thymus. Binding was time, temperature and concentration-dependent belonging in the range of concentrations of radioligand used to a single class of high affinity sites. The dissociation constant was 1.6 nM and the maximal density of binding sites averaged to 170 fmol/mg tissue. The pharmacological profile of [3H]SCH 23390 binding to sections of the rat thymus is consistent with the labelling of dopamine D1-like sites. Dopamine was able to compete with [3H]SCH 23390 binding to sections of rat thymus in the range of nanomolar concentrations. This suggests the labelling of dopamine D5 receptor sites. Light microscope autoradiography revealed the localisation of [3H]SCH 23390 binding sites primarily in the cortex of the thymus and in lesser amounts at the level of thymic corpuscles. The possible functional significance of dopamine D1-like receptors in the rat thymus is discussed.

3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes

In order to investigate the diagnostic value of 3H-spiperone binding capacity to lymphocytes in the differential diagnosis of de novo Parkinson's disease (idiopathic Parkinson syndrome, PD), we performed a double blind prospective study of spiperone binding capacity of 123 patients and 23 healthy control persons, belonging to different diagnostic groups (PD, Parkinsonian syndrome due to vascular lesions, multiple system atrophy [MSA], essential tremor). Diagnoses were based on medical history, clinical examination, CT or MRI scan, acute response to dopamimetic drugs, one year follow up, and long term response to L-DOPA treatment. Spiperone binding was assayed using ten different concentrations (0.03-3 nmol) in absence or presence of 1 mumol (+)-butaclamol to determine nonspecific binding. There was no significant difference in spiperone binding between patients with PD not treated with L-DOPA, and patients with other basal ganglia disorders including parkinsonian syndrome due to vascular lesions, multiple system atrophy, or progressive supranuclear palsy, and age matched controls. Binding was significantly higher in parkinsonian patients with PD treated with L-DOPA and patients with essential tremor. It is concluded that at present 3H-spiperone binding gives no further information in the differential diagnosis of de novo Parkinson's disease.

3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects

3H-spiroperidol binding to peripheral blood mononuclear cells was measured in 28 patients, who fulfilled DSM-III-R-criteria for schizophrenia and 17 healthy subjects. There were no significant differences in characteristic binding parameters (Kd, Bmax) between schizophrenic and healthy subjects. Moreover, there was no relation of binding parameters to any of the subtypes of schizophrenia or to the course of illness according to DSM-III-R-criteria. However, some patients exhibited higher Bmax values without having a unique clinical symptomatology according to known diagnostic criteria. Neuroleptic treatment had no consistent effect on binding parameters intraindividually. Kd and Bmax values were not related to age or gender. In conclusion, despite our previously reported improved methodology, we were not able to corroborate the clinical importance of this "peripheral marker" as a tool for diagnosing schizophrenia or for predicting the response to neuroleptic treatment in our sample of schizophrenic patients.

Inhibition of cutaneous contact hypersensitivity in the mouse with systemic or topical spiperone: topical application of spiperone produces local immunosuppression without inducing systemic neuroleptic effects

We tested the ability of the neuroleptic agent spiperone (8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-1,3,8-triazaspiro-[4.5] decan-4- one) to influence the tissue swelling and leukocyte infiltration associated with T-cell--dependent immune responses, i.e., contact hypersensitivity reactions, in mice. Contact hypersensitivity reactions were elicited by applying the haptens oxazolone or dinitrofluorobenzene topically to one or both ears 5-8 d after epicutaneous sensitization. When spiperone was given subcutaneously at a dose of 30 or 150 mg/kg, 1 h after challenge with oxazolone, cutaneous contact hypersensitivity to this hapten was significantly diminished. When applied topically in concentrations as low as 0.08% (w/w), preparations of spiperone significantly suppressed both the tissue swelling and the leukocyte infiltration associated with the elicitation phase of contact hypersensitivity. Topical treatment with spiperone also suppressed the sensitization phase of contact sensitivity. However, mice treated topically with spiperone, unlike those treated systemically, exhibited no drowsiness or other evidence of central nervous system effects. Spiperone expresses both serotonin and dopamine receptor antagonist activity. However, unlike spiperone, the chemically unrelated serotonin antagonists, trazadone and mianserin, and the dopamine receptor antagonist, haloperidol, were not effective in suppressing contact hypersensitivity. Our results indicate that spiperone can have immunosuppressive effects on contact hypersensitivity reactions in the mouse, even when applied topically in doses that lack neuroleptic effects, and that the mechanism of action of spiperone on the immune response may be independent of its serotonin or dopamine receptor blocking properties.

3H-spiroperidol binding to human peripheral mononuclear cells: methodological aspects

3H-spiroperidol binding to lymphocytes has been proposed as a vulnerability marker for schizophrenia. However, the biological significance and even existence of this "binding site" are still in controversy. Therefore, the present study reevaluated methodological details using a filtration binding assay. The results indicated that some well-known, but obviously uncontrolled pitfalls might contribute to this controversy [e.g., unspecific filter binding, which increased in the presence of (+)-butaclamol, or a variable amount of contaminating granulocytes). Moreover, due to an atypically shaped saturation curve, different mathematical methods to analyze the data were used and compared. The present data should help us to understand the biological relevance of this marker, as viewed in different laboratories.

The sequestration of [3H]spiperone by lymphocytes in schizophrenics and their first-degree relatives: a limited vulnerability marker?

The sequestration of [3H]spiperone by lymphocytes was studied in preserved cells obtained from 22 schizophrenic subjects and 40 of their relatives, and the results were compared with those obtained from 25 healthy control subjects. Mean displaceable sequestration values, obtained from measurements made at a single radioligand concentration (1nM) which optimised the relative contribution of "high affinity" sequestration, were found to be similar for all groups of subjects. Furthermore, displaceable spiperone sequestration was abnormally high in only a small proportion of the schizophrenics (13.6%) and their relatives (5%). There was no evidence that either exposure to neuroleptic medication or duration of illness had an effect on sequestration values. The results suggest that, at least until the required experimental conditions are better established, [3H]spiperone sequestration by lymphocytes does not offer a useful vulnerability marker for schizophrenia.

3H-spiperone labels sigma receptors, not dopamine D2 receptors, in rat and human lymphocytes

3H-Spiperone binds to dopamine D2 receptors in striatum and, under the assumption that it labels the same receptors in lymphocytes, this binding site has been suggested as a biological marker for schizophrenia. Recent studies, however, have raised questions about the existence of dopamine receptor changes in drug-free schizophrenic patients, as well as on the presence and/or dopaminergic nature of lymphocytic 3H-spiperone binding sites. In the present study we have conducted an investigation of the binding of 3H-spiperone to rat and human lymphocytes. We found that 3H-spiperone binds in a specific, saturable and reversible manner to a site in lymphocytes; however, its dissociation constant Kd (9 nM) is about 40-fold higher than in striatum. An extensive investigation of the 3H-spiperone sites indicated that their pharmacological profile was not that of a dopamine D2 site, but rather that of sigma receptors, a novel class of non-dopaminergic, non-opioid receptors which bind with high affinity antipsychotic drugs. Sigma receptors were also identified in lymphocytes using the specific ligand 3H-DTG (1,3-di-o-tolyl-guanidine), whose binding characteristics were comparable to those of sigma receptors in rat brain. Receptor density and the pharmacological profile of 3H-spiperone and 3H-DTG were similar. Both compounds also labelled a higher number of sites in B cells than in T cells and a good correlation was found between the lymphocytic binding of both ligands in a group of 58 people. These findings indicate that sigma receptors are present in lymphocytes and suggest that 3H-spiperone binding in these cells occurs to sigma sites and not to dopamine D2 sites.

A specific effect of antipsychotic drugs on protein synthesis in human lymphomononuclear cells

We have studied the effects of psychotropic drugs on patterns of protein synthesis in human lymphomononuclear cells by two-dimensional gel electrophoretic analysis. Drugs effective in treatment of schizophrenia specifically increased the relative synthesis of a 30-kDa polypeptide in cultured human lymphomononuclear cells whereas dopamine (DA) or psychoactive drugs lacking antipsychotic properties did not. The effect was stereospecific with respect to the clinically active and inactive isomers of flupenthixol. Synthesis of the 30-kDa polypeptide appears therefore to be correlated with antipsychotic properties but not with DA receptor binding. It is possible that such effects may be associated with the clinically beneficial effect of antipsychotic drugs in the brain.

Failure to find interference between anti-HLA antibodies and chlorpromazine

Chlorpromazine has been reported to interfere with the action of alloantibodies directed against HLA-A1. We attempted to replicate this finding using peripheral blood lymphocytes from 3 healthy donors in a complement-mediated lymphocytotoxicity assay. We were unable to find evidence of interference between chlorpromazine and the anti-HLA sera tested. Possible reasons for the difference between our finding and the previous report, as well as the implications for schizophrenia, are discussed.

Methodology of 3H-spiperone binding to lymphocytes

Alterations in lymphocyte binding capacity for the dopamine antagonist 3H-spiperone may be of great interest in psychiatric and neurological disorders: an increase in capacity noted in lymphocytes of schizophrenic patients and their families may well turn out to be a phenotypic vulnerability marker. Since the 3H-spiperone binding assay with lymphocytes does not fulfill common receptor-binding assay criteria and depends more on crucial analytical conditions, shortcomings in binding assay might possibly lead to irreproducible results. A detailed methodological description of the binding assay and subsequent calculations has therefore been given in this paper.

Binding of 3H-spiperone to human peripheral lymphocytes: absence of stereospecific high-affinity binding

The binding of 3H-spiperone to human peripheral lymphocytes (PBL) was characterized. The (+)-butaclamol displaceable binding of 3H-spiperone was not saturable, and both (+) and (-)-butaclamol were equally potent in displacing 3H-spiperone binding. We did not find evidence for the existence of a high-affinity specific binding site of 3H-spiperone on human PBL.

Inhibition of lipopolysaccharide-induced alpha/beta-interferon synthesis by dopamine and the dopamine-1 agonist fenoldopam

In vitro incubation of Listeria monocytogenes-immune spleen cells in the presence of dopamine or fenoldopam, a dopamine-1 (D1) agonist, inhibited alpha/beta-interferon (IFN) synthesis induced by the mitogen lipopolysaccharide (LPS), in a manner that appeared to be concentration dependent. In addition, the inhibitory effect of dopamine and fenoldopam on the synthesis of IFN was prevented by incubating immune spleen cells in the presence of haloperidol, a D1 antagonist.

Uptake of 3H-spiperone by lymphocytes in schizophrenia

Uptake of 3H-spiperone into lymphocytes obtained from control subjects (N = 22), chronic schizophrenics (N = 20), relatives with psychiatric disorder (N = 11) and unaffected relatives (N = 17) was studied. No differences were observed in spiperone uptake among any of the groups examined. Although previous investigations reported marked differences in 3H-spiperone uptake between schizophrenic and control subjects, we were unable to replicate their findings: the failure to replicate those of Bondy and colleagues may well be due to our inability to duplicate in our laboratory the exact biochemical methodology described by these investigators. Saturation curves could not be determined for most subjects. In addition, chronicity of illness and long-term exposure to neuroleptic medication among the schizophrenic subjects may partially account for the contradictory results reported by different investigators.

Opposite effects of the catecholamines dopamine and norepinephrine on murine polyclonal B-cell activation

The effects of dopamine (DA) and norepinephrine (NE) on polyclonal B-cell activation induced in vitro by lipopolysaccharide (LPS) and on cyclic AMP response in BALB/c mouse lymphocytes were investigated. DA at non-cytotoxic concentrations (5 x 10(-5) M and 10(-4) M) inhibited, but NE (5 x 10(-6) M to 5 x 10(-5) M) enhanced LPS-stimulated proliferation and Ig synthesis by lymphocytes from spleen, mesenteric lymph nodes and Peyer's patches. Depletion of adherent cells and T lymphocytes did not prevent the respective effects of DA and NE, and the drug effects were reproduced on nude (nu+/nu+) spleen cell proliferation and differentiation stimulated by LPS. The inhibitory effect of DA persisted even if the drug was added as late as 48 h after the mitogen. In contrast, NE was no longer stimulatory if added 2 h later than LPS. The effect of DA was blocked neither by DA1 or DA2 dopaminergic antagonists (SCH 23390 and sulpiride respectively), nor by alpha- or beta-adrenoceptor antagonists (phentolamine and propranolol respectively). Enhancement by NE was antagonized by propranolol, but not by phentolamine. Both DA and NE raised the level of cyclic AMP in unfractionated spleen cells as well as in B-enriched spleen cells but DA was less potent than NE. Pre-incubation of spleen lymphocytes with LPS for 1-24 h did not alter their cyclic AMP response to NE but it prevented the loss of sensitivity to DA after 4 or 24 h of in vitro incubation. The lysosomotropic agent chloroquine induced suppression of LPS-stimulated proliferation and Ig production with a dose-response profile similar to that of DA. Altogether, these results indicate that the catecholamines can exert opposite effects on polyclonal B-cell activation by acting directly on B lymphocytes.

Cyclic adenosine 3',5'-monophosphate response to dopamine in mouse lymphoid cells and cell lines

Cyclic adenosine 3',5'-monophosphate responses to dopamine and isoproterenol were studied in mouse and rat spleen, thymus, lymph nodes and Peyer's patches lymphocytes and in 7 mouse cell lines of T- and B-lymphoid derivation. The responses of normal cells to dopamine were moderate, of the same extent, but selective to spleen and thymus in mouse, and to spleen and lymph nodes in rat. The YAC-1 T lymphoma cell line was sensitive to dopamine with a higher magnitude than normal lymphoid cells. Dopamine was less potent than isoproterenol in all cells, and whereas dopamine-sensitive and isoproterenol-sensitive cells, or dopamine-insensitive and isoproterenol-insensitive cells were found, no cell type was dopamine-sensitive and isoproterenol-insensitive. Altogether, these results suggest that only a small subset of lymphocytes is susceptible to the cAMP-elevating action of dopamine.

Variations in age-related decline in striatal D2-dopamine receptors in a variety of mouse strains

To determine the importance of inheritance on the age-associated decline in D2-dopamine receptor number, the binding of [3H]spiperone to mouse striatal membranes was measured in animals ranging from 7 to 104 weeks of age from 5 murine strains (C57BL/6J, C3/HeJ, A/J, SJL/J and DBA/1J). In young mice, receptor number (Bmax) was influenced by genetic background such that C57BL/6J less than SJL/J less than A/J = DBA/1J = C3H/HeJ. A 50-60% decline in Bmax with age was found in all strains except for C57BL/6J. Bmax in the C57BL/6J mice were lower than in the other strains of young animals (7-15 weeks) but remained relatively constant throughout life (measured up to 104 weeks of age). Furthermore, the maximal decline in receptor number was observed relatively early in life (16-30 weeks) and remained constant thereafter. Neither age nor genetic background influenced ligand affinity (Kd). Thus the results of this study suggest that the maximal decline in Bmax for the dopamine receptor occurs before the second half of life and that the magnitude of this decline is polymorphic.

Dopamine receptors and the dopamine hypothesis of schizophrenia

The discovery of neuroleptic drugs in 1952 provided a new strategy for seeking a biological basis of schizophrenia. This entailed a search for a primary site of neuroleptic action. The Parkinsonian effects caused by neuroleptics suggested that dopamine transmission may be disrupted by these drugs. In 1963 it was proposed that neuroleptics blocked "monoamine receptors" or impeded the release of monoamine metabolites. The neuroleptic concentration in plasma water or cerebrospinal fluid was of the order of 2 nM for haloperidol in clinical therapy. A systematic research was made between 1963 and 1974 for a primary site of neuroleptic action which would be sensitive to 2 nM haloperidol and stereoselective for (+)-butaclamol. Direct evidence that neuroleptics selectively blocked dopamine receptors occurred in 1974 with the finding that nanomolar concentrations of these drugs stereoselectively inhibited the binding of [3H]-dopamine or [3H]-haloperidol. These binding sites, now termed D2 dopamine receptors (which inhibit adenylate cyclase), are blocked by neuroleptics in direct relation to the antipsychotic potencies of the neuroleptics. No such correlation exists for D1 receptors (which stimulate adenylate cyclase). Based on the fact that dopamine-mimetic drugs elicited hallucinations, and that neuroleptics caused rigidity, Van Rossum in 1966 had suggested a hypothesis that dopamine pathways may be overactive in schizophrenia. The D2-selective blockade by all neuroleptics (except the monoamine-depleting reserpine) provided strong support for the dopamine hypothesis. Further support now comes from postmortem data and in vivo positron tomographic data, both of which indicate that the density of D2 receptors are elevated in the schizophrenic brain. The postmortem data indicate a bimodal pattern with half the schizophrenics having striatal D2 densities of 14 pmol/g (control is 13 pmol/g) and the other half having 26 pmol/g. Current positron tomographic data indicate D2 densities of 14 pmol/g in control subjects, but values of 34 pmol/g in drug-naive schizophrenics. Future tests of the dopamine hypothesis of schizophrenia may entail an examination of the amino acid composition and genes for D2 receptors in schizophrenic tissue, an examination of the ability of the D2 receptor to become phosphorylated and to desensitize into the low-affinity state, and an examination of the interaction of D2 receptors with D1 receptors or other neurotransmitters.

Selective T cell defects induced by dopamine administration in mice

Dopamine administration in BALB/c mice depressed the overall delayed-type hypersensitivity reaction to sheep red blood cells, the mixed-lymphocyte culture responses, the generation of cytotoxic T cells, and the number of spleen T cell populations. Conversely, dopamine enhanced concanavalin A stimulation of spleen cells, and had no effect on stimulation by PHA, on total spleen and thymus cell number, and on distribution of thymus Ly-t1+ or Ly-t2+ cell subsets. These results indicate that dopamine produces selective T cell defects probably mediated by a direct peripheral action of the drug on subsets of T lymphocytes.

3H-spiperone binding sites in lymphocytes as possible vulnerability marker in schizophrenia

The binding parameters for the dopamine antagonist 3H-spiperone to lymphocytes were investigated in nonmedicated schizophrenics (N = 43), in medicated schizophrenics (N = 25), as well as in 38 first- and second-degree relatives of schizophrenics, in a psychiatric control group (N = 27) and in normal, healthy controls (N = 40). The density of lymphocyte 3H-spiperone binding sites (Bmax) was significantly increased in all acute and chronic schizophrenic patients and in patients undergoing neuroleptic treatment for 2 weeks to several months and remained on a constant level during a drug-free remission period, suggesting that Bmax is a state independent variable. Elevated binding seems to be associated with schizophrenia; it could not be found in other psychiatric patients. In pedigree and family studies it became obvious that all relatives with one or more previous episodes of schizophrenia had similar increased binding capacity. But even in some well-state relatives elevated spiperone binding could be found, although they never had symptoms of the disease. Among these relatives of schizophrenics, there was an association between increased spiperone binding and the transmission of the disease. Although conclusive data about the precise genetic control obtainable in twin studies are still missing, we would suggest that elevated lymphocyte spiperone binding may be a marker of susceptibility to schizophrenia.

Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?

The specific binding of the dopamine antagonist 3H-spiperone to lymphocytes from a healthy control group (n = 40), a group of acute, unmedicated schizophrenic patients (n = 27), and a psychiatric control group (n = 16) was investigated. There were no differences in binding parameters between the healthy controls (Bmax 2.6 +/- 0.7 fmoles/10(6) cells; Kd 0.17 +/- 0.07 nM) and the psychiatric control group. Binding capacity of 3H-spiperone was significantly increased in lymphocytes from the schizophrenic patients (Bmax 14.4 +/- 9.3 fmoles/10(6) cells). Moreover, a slight decrease in affinity was observed (Kd 0.44 +/- 0.21 nM). Because the increase in binding appeared only in schizophrenic patients, this peripheral model could prove valuable as a diagnostic criterion.

Reduced binding of 3H-spiroperidol to lymphocyte in Wilson's disease

Biochemical studies of CSF from patients with Wilson's disease (WD) have increased that alterations in the state of dopaminergic and serotoninergic systems are similar to those manifested in Parkinson's disease. Recently, the density of dopaminergic receptors on lymphocytes has been found to be diminished in Parkinson's disease. In the present study, 3H-spiroperidol binding was evaluated in lymphocytes acquired from 12 patients suffering from WD, as compared to blood donors. A significant decrease in the number of binding sites (Bmax) was observed in the lymphocytes of the WD patients. There was no clear relationship between clinical status, age and duration of the disease and the alterations in receptor density. The mechanism underlying the decrease in lymphocyte 3H-spiroperidol binding sites in WD demands clarification.

Failure of a peripheral dopaminergic marker in Parkinson's disease

[3H]-spiperone binding on human lymphocytes did not reveal the occurrence of dopamine receptors. However, lower values were observed in Parkinsonism and the displaceable binding was increased after levodopa treatment although this was not specific only for levodopa and, furthermore, was not correlated with the clinical symptomatology. This non-specific binding in lymphocytes corresponds to trapping, presumably in lysosomes and thus does not reflect the dopaminergic receptors state in Parkinson's disease.

Trapping of labelled ligands in intact cells: a pitfall in binding studies

Binding on/in whole cells seems to be a more appropriate approach for studying receptor sites in physiological conditions. However, certain difficulties encountered throughout the characterization of [3H]spiperone binding in human lymphocytes led us to reconsider this problem. The IC50 values of [3H]spiperone binding to human lymphocytes did not correlate with those found in rat striatum; domperidone was inactive in lymphocytes whereas it is one of the most potent dopamine antagonists in rat striatal preparations in vitro. In contrast, chloroquine, a lysosomotropic drug, displaced [3H]spiperone at low concentration in intact lymphocytes but did not in the striatum. [3H]Spiperone binding was not displaceable in the membrane preparation of lymphocytes. Similar results were obtained with other intact cells, fibroblasts, hepatocytes and neuroblastoma cells using [3H]spiperone and other ligands, such as [3H]haloperidol, [3H]pyrilamine and [3H]ketanserin. Here again, displaceable binding was only present in intact cells but not in membrane fractions. Such a 'displaceable' binding was not related to receptor sites but may be regarded as non-specific binding which should correspond to a trapping phenomenon presumably in the lysosomes. Binding studies on intact cells need more caution than when performed on membrane preparations; indeed, permeation or trapping of ligands in the nanomolar range represents a serious drawback which, sometimes, can give the illusion of specific binding.

Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings

Binding of 3H-spiroperidol was determined in ten (10) unmedicated recently admitted and four (4) drug holiday schizophrenic patients to determine whether it could serve as a peripheral marker of central dopaminergic hyperactivity. Preliminary results indicate significantly increased binding but there is considerable intersubject variability. Displacement studies, the lack of stereospecificity and the necessity of having an intact lymphocyte do not indicate that this is binding to a dopamine receptor but rather an uptake phenomenon.